Advertisement
01/28/2021

Smart Meter debuts cell-enabled iBloodPressure Monitor

David Salazar
Managing Editor
David Salazar profile picture

As it looks to grow its capabilities in enabling remote patient management, Smart Meter is introducing a new connected health tool. The iBloodPressure is a cellular-connected blood pressure monitor that includes a 4G/5G LTE communication chip allowing for reading results to be automatically transmitted to a patient’s remote patient monitoring portal, without the need for syncing, apps, smartphones, Wi-Fi or docking stations.

“Our user base has grown nearly tenfold, a testament to the fact that Smart Meter makes it easy for healthcare providers, patients and organizations to implement and scale sustainable RPM programs in a matter of weeks, supporting patient populations of all sizes,” said Brahim Zabeli, CEO of Smart Meter. “Our cellular-enabled iBloodPressure Monitor and iGlucose Blood Glucose Meter do not require patient setup. Rapid onboarding and instant transmission of data fulfills CPT requirements for efficient reimbursement.”

Smart Meter said that its products are designed to provide secure, consistent and accurate data, with the aim of enabling a higher level of patient care and the potential for improved patient outcomes.

“[Remote patient monitoring] evolved as a rapidly adopted mode of care delivery in 2020, of which Smart Meter has been an integral part in bridging the historic in-person care setting,” said  Dr. Bill Lewis, principal at WellMedCare Consulting. “The addition of the new cellular-enabled iBloodPressure cuff to its digital offerings will complement a growing suite of cellular monitoring devices, enabling chronic care disease management.”

“The simplicity of activation, monitoring and utilization of these devices partially circumvents many of the healthcare access hurdles of digital literacy for the elderly,” he said. “For clinical care organizations, their job just became easier. Smart Meter’s suite of products now enables RPM to improve clinical and medication adherence, as well as endpoint clinical outcome measurements like A1C and HBP.”

Advertisement
Advertisement